Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Results of the 2022-2025 Elections – Executive Committee and Council Members  

November 21, 2022

News from ICLAS – November Bulletin

November 17, 2022

IUIS ImmunoArgentina 2022 and 2nd Argentinean Spring Course In Advanced Immunology (ASCAI-II)

November 10, 2022Education Committee (EDU)

EDU/IUIS-BIS WORKSHOP 2022 Report – Flow cytometry: from basic principles to research applications

November 10, 2022Education Committee (EDU)

IUIS Newsletter September 2022

October 6, 2022

Deadline Extension – Nominations for IUIS Elections 2022

June 30, 2022

SCGES Webinars in June – on Gender Equality

June 2, 2022Gender Equality Committee (GEC)

Menarini Prize for Outstanding Woman Immunologist

May 31, 2022Gender Equality Committee (GEC)

2022 Edition: Day of Immunology

May 19, 2022